28 June 2024 - Positive recommendation is based on two Phase 3 studies. In addition to robust retinal drying with Vabysmo, these data show early and sustained vision improvements, which are non-inferior to aflibercept.

Roche announced today that the EMA’s CHMP has adopted a positive opinion for the extension of the Vabysmo (faricimab) marketing authorisation to include the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion.

Read Roche press release